Tivic Health Systems

TIVC

Market cap $2.17M

January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure BARDA has requested a follow-up meeting to continue the discussion on the potential utility of Entolimod as a drug for the Strategic National Stockpile Showcased clinical results, regulatory progression, and manufacturing readiness accelerated by newly formed subsidiary Velocity Bioworks™ FREMONT, CA / ACCESS Newswire / January 28, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that it delivered an invited presentation at a TechWatch meeting with the Biomedical Advanced Research and Development Authority (BARDA) on January 26, 2026, with select members of the Department of Defense (DoD), Defense Threat Reduction Agency (DTRA), National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID). The company presented key clinical and manufacturing readiness data for Tivic's Toll-like Receptor 5 (TLR5) agonist, Entolimod™, underscoring its potential use as a radiation countermeasure, as well as progress on manufacturing readiness that has been accelerated by newly formed subsidiary Velocity Bioworks.

CEO Presentation to Include Updates and Further Information on the Following Topics: Entolimod Cell Line Verification Success; 200x Manufacturing Scale-Up with Reproducible Quality; BARDA TechWatch Engagement; Creation of Velocity Bioworks, An Integrated CDMO To Accelerate Commercial Readiness FREMONT, CA / ACCESS Newswire / January 26, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that the company's CEO will present at the 3rd Annual DealFlow Discovery Conference, set to take place on January 28-29, 2026 in Atlantic City, New Jersey. Event Details 3rd Annual DealFlow Discovery Conference The Borgata Hotel, Casino & Spa Atlantic City, NJ January 28-29, 2026 Investors interested in scheduling a meeting with the Tivic's management team should request an investor pass to attend the conference (no cost to attend).

Presentation will Cover Recent Corporate Milestones Including Acceleration of Manufacturing Readiness for Entolimod™ FREMONT, CA / ACCESS Newswire / January 20, 2026 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage immunotherapeutics company, today announced that its CEO will provide a corporate update focused on recent developments in its advancement of Entolimod ™ during the Emerging Growth Virtual Conference on January 21 and 22, 2026 WHO: Jennifer Ernst, Chief Executive Officer WHERE: January 22, 2026 WHEN: 4:10 - 4:20 Eastern Time During the virtual conference update, Ms. Ernst will highlight recent company developments, including scale-up validation for Entolimod manufacturing and the vertical integration of Velocity Bioworks-a San Antonio-based contract development and manufacturing organization which provides the company with in-house manufacturing capability and new potential revenue streams.

Tivic Health Systems, Inc. (TIVC) Discusses Acquisition of Biomanufacturing Assets and Strategic Transformation Transcript

Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly owned contract development manufacturing organization (CDMO), Velocity Bioworks Company's next step is to initiate production under current Good Manufacturing Practice (cGMP), a critical milestone moving towards filing a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) Milestone achieved in advance of January 26 TechWatch meeting with the Biomedical Advance Research and Development Authority (BARDA) to discuss federal strategic relevance of Entolimod™ for ARS FREMONT, CA AND SAN ANTONIO, TX / ACCESS Newswire / January 12, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced it has delivered a 200x scale-up in manufacturing volume for Tivic's lead drug candidate Entolimod™. Entolimod is a TLR5 agonist in development to treat ARS, as well as Neutropenia and other cancer-related conditions.

Conference Call to be Hosted on Monday, January 12 at 1:30 PM PT/4:30 PM ET FREMONT, CA / ACCESS Newswire / January 8, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that Management will host a special conference call to further discuss the company's recent acquisition of certain contract development and manufacturing organization (CDMO) assets as announced on December 11, 2025. The call will cover how the acquisition has accelerated key strategic priorities and development and commercialization timelines, as well as discuss other near-term potential benefits.

Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™ Financing led by 3i, LP includes $16M debt financing for the purchase of assets and up to $75M in preferred convertible equity available for therapeutics commercialization and corporate growth initiatives FREMONT, CA AND SAN ANTONIO, TX / ACCESS Newswire / December 11, 2025 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a diversified therapeutics company, today announced it has acquired the strategic manufacturing and development assets of Scorpius Holdings, Inc. and is launching Velocity Bioworks™, a wholly owned subsidiary of Tivic, to provide contract development and manufacturing services to Tivic and other companies. Strategic advantages of this acquisition and the formation of Velocity Bioworks include: Secures a robust US-based manufacturing site for Tivic's lead drug candidate Entolimod™ as the company moves towards a Biologics License Application (BLA) with the U.S. Food & Drug Administration.

Meeting with Radiological and Nuclear Medical Countermeasures Program FREMONT, CA / ACCESS Newswire / November 18, 2025 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage therapeutics company, today announced it has secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority (BARDA)'s Radiological and Nuclear Medical Countermeasures Program staff. Tivic leadership will be presenting clinical data on Entolimod's effects on radiation-induced injury and acute radiation syndrome (ARS), its progress on manufacturing readiness and the preparations it has been making for a biologics license application, or BLA.

Continues Execution of Strategic Transformation and Advancement of Biologics Pipeline FREMONT, CA / ACCESS Newswire / November 14, 2025 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a diversified immunotherapeutics company, today announced financial results for the third quarter and nine months ended September 30, 2025 and provided a business update. "Following our discussions at the Military Health System Research Symposium and continued engagement with key government agencies, we are encouraged by the interest in our lead product candidate, Entolimod for acute radiation syndrome (ARS), as a military medical countermeasure and stockpile drug," stated Tivic CEO, Jennifer Ernst.

The study demonstrated that personalizing the stimulation parameters to each user dramatically enhanced autonomic effects FREMONT, CA / ACCESS Newswire / November 13, 2025 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a diversified immunotherapeutics company, announced today it has optimized key device and treatment parameters including frequency, amplitude, electrode positioning, and duration of stimulation as a result of its collaborative study with The Feinstein Institutes for Medical Research at Northwell Health. Physiological measurements taken before, during, and after ncVNS treatment found the following: Personalizing the frequency of ncVNS stimulation to each study subject resulted in a 46% increase in heart rate variability, which was 8.9x more effective than applying the same frequency to all subjects The optimal ncVNS frequency for each subject was found to be different between visits, indicating the importance of personalizing the stimulation parameters before each treatment Certain placement and configurations of electrodes were found to be more effective than others, with some placements increasing heart rate variability and others markedly reduce heart rate variability Four minutes of ncVNS stimulation was sufficient to drive a large increase in heart rate variability and was more effective than twenty minutes of stimulation.